KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Finished Goods (2018 - 2026)

Alnylam Pharmaceuticals (ALNY) has disclosed Finished Goods for 9 consecutive years, with $39.0 million as the latest value for Q1 2026.

  • For Q1 2026, Finished Goods rose 18.25% year-over-year to $39.0 million; the TTM value through Mar 2026 reached $39.0 million, up 18.25%, while the annual FY2025 figure was $32.3 million, 22.34% up from the prior year.
  • Finished Goods hit $39.0 million in Q1 2026 for Alnylam Pharmaceuticals, up from $32.3 million in the prior quarter.
  • Across five years, Finished Goods topped out at $39.0 million in Q1 2026 and bottomed at $10.4 million in Q1 2022.
  • Average Finished Goods over 5 years is $27.1 million, with a median of $27.7 million recorded in 2023.
  • On a YoY basis, Finished Goods climbed as much as 265.54% in 2022 and fell as far as 24.18% in 2022.
  • Alnylam Pharmaceuticals' Finished Goods stood at $25.6 million in 2022, then dropped by 1.89% to $25.1 million in 2023, then increased by 5.21% to $26.4 million in 2024, then increased by 22.34% to $32.3 million in 2025, then increased by 20.54% to $39.0 million in 2026.
  • According to Business Quant data, Finished Goods over the past three periods came in at $39.0 million, $32.3 million, and $38.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.